Who
Berndt Modig
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Pharvaris; Director, Sio Gene Therapies.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $2.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 Apr 2016
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $10.5M300,000 at $35.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $10.5M300,000 at $35.00 | filing |
| 14 Sep 2026filed 15 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $90K2,291 at $39.40 | filing |
| 14 Sep 2026filed 15 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $90K2,291 at $39.40 | filing |
| 14 Aug 2026filed 18 Aug 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $80K2,292 at $34.77 | filing |
| 14 Aug 2026filed 18 Aug 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $80K2,292 at $34.77 | filing |
| 13 Jul 2026filed 15 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $80K2,292 at $34.97 | filing |
| 13 Jul 2026filed 15 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $80K2,292 at $34.97 | filing |
| 15 Jun 2026filed 17 Jun 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $68K2,191 at $31.05 | filing |
| 15 Jun 2026filed 17 Jun 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $3,146100 at $31.46 | filing |
| 15 Jun 2026filed 17 Jun 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $68K2,191 at $31.05 | filing |
| 15 Jun 2026filed 17 Jun 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $3,146100 at $31.46 | filing |
| 18 May 2026filed 20 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $67K2,292 at $29.22 | filing |
| 18 May 2026filed 20 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $67K2,292 at $29.22 | filing |
| 16 Apr 2026filed 20 Apr 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $66K2,292 at $28.60 | filing |
| 16 Apr 2026filed 20 Apr 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $66K2,292 at $28.60 | filing |
| 9 Apr 2026filed 10 Apr 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $642K23,133 at $27.74 | filing |
| 9 Apr 2026filed 10 Apr 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $5,683200 at $28.42 | filing |
| 9 Apr 2026filed 10 Apr 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $642K23,133 at $27.74 | filing |
| 9 Apr 2026filed 10 Apr 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $5,684200 at $28.42 | filing |
News
No headline names them, or the companies they trade most, lately.